By using the Cape Capital website (“Website”), you declare that:
By clicking “Accept all” you acknowledge and accept the following Important Legal Information and Terms of Use:
The content of this Website (including microsites) has been prepared by Cape Capital AG, with its registered address at Utoquai 55, 8008 Zurich, Switzerland (“Cape Capital”), duly registered at the commercial register of the Canton of Zurich with number CHE-109.617.147. and contains the views and opinions of the particular individuals and is for general information and marketing purposes only. All copyrights and other rights, included but not limited to logos and registered trademarks relating to the entire content of the Website are reserved exclusively to Cape Capital or the specifically designated right holders. Any use, in particular the reproduction or publication in full or in part is permitted only with the prior written consent of Cape Capital. Cape Capital may from time to time suspend the operation of this Website for repair, maintenance or improvement work, or in order to update or upgrade its content or functionality. Cape Capital may also change the format, content and/or access of this Website at any time at its sole discretion without notice. Although Cape Capital believes that information provided on this Website is based on reliable sources, content on this Website is presented only as of the date published or indicated, and may be superseded by subsequent market events or for other reasons. Therefore Cape Capital cannot assume responsibility for the quality, correctness, timeliness or completeness of the information contained herein. Unless otherwise stated, the numbers/figures on the Website are unaudited.
Cape Capital is a regulated asset manager of collective assets according to the Federal Act on Financial Institutions of 15 June 2018 (FinIA) and supervised by the Swiss Financial Market Supervisory Authority FINMA, Laupenstrasse 27, CH-3003 Bern, Switzerland (FINMA). The Website contains information about various collective investments (“Funds”) which may have been registered or otherwise notified for distribution and marketing in the jurisdiction you have selected. Please note, that such registration or notification does not mean that the Funds are suitable for all investors and their investment objectives, financial situation and risk profile. As an asset manager of collective assets, Cape Capital is, among others, subject to the rules under the Swiss Financial Services Act (FinSA), the Swiss Collective Investment Schemes Act (CISA) and the Swiss Financial Institutions Act (FinIA).Cape Capital is affiliated to the following Ombudsman according to FinSA: Finanzombudsstelle Schweiz (FINOS), Talstrasse 20, CH-8001 Zurich, Switzerland. For further information, please refer to the General Client Information Document available on the Website which forms an integral part of these Conditions.
Nothing contained on this Website constitutes a solicitation, an offer or a recommendation to buy or sell any Cape Capital Funds or other financial instruments, nor does it constitute any form of personal investment advice which takes into account your personal circumstances. Cape Capital does not provide investment, legal, tax or other advice through this Website and nothing herein should be construed as such advice. Cape Capital does not represent that any Cape Capital collective assets or financial instruments mentioned on this Cape Capital website are suitable for any investor. Investment or other decisions should be made solely on the basis of the relevant product and/or service documents (prospectus/offering memorandum, fund contract/articles, key information documents, financial reports) of the respective collective investment. If not a Cape Capital client, it is strongly recommended to contact a professional financial advisor, tax consultant or other qualified expert in order to determine whether an investment in a Fund or other financial instrument corresponds to the specific requirements and preferred level of risk of the investor.
Any collective investment schemes mentioned on this Website may, unless explicitly stated otherwise, not be offered, sold or delivered to United States (U.S.) citizens or persons resident or incorporated in the U.S. and/or other natural or legal persons whose income and/or returns, regardless of origin, are subject to U.S. income tax, as well as persons who are considered to be U.S. persons pursuant to Regulation S of the U.S. Securities Act of 1933 and/or the U.S. Commodity Exchange Act, in each case as amended from time to time.
The provision of financial services and investments in Funds and other financial instruments involve opportunities but also bear risks, including the risk that the value of investments and the income therefrom may fall or rise and investors may not get back the full amount invested or may even lose all of their investment. Investors should ensure to have fully understood such risks before taking any investment decisions. Cape Capital strongly advises to consult the brochure “Risks Involved in Trading Financial Instruments” of the Swiss Bankers Association (SBA) as well as the relevant documents of the respective Fund or financial instrument and to seek professional investment advice before taking any decision to invest. Investors should note, that these Conditions do not represent a complete statement of risks associated to a Fund or a financial instrument. Past performance is no indication of current or future performance. Performance data do not include commissions and costs incurred by investors when subscribing or redeeming Fund shares.Investments, in particular collective investments in private equity, venture capital and other illiquid assets involve an above-average degree of risk, including the risk that losses may even exceed the original investment and should be seen as long-term in nature.
The use of this Website, including any information accessed, downloaded or otherwise obtained through the Website is at your own risk. This Website, together with all content, information and materials contained therein, is provided “as is” and “as available”, without any representations or warranties of any kind, whether express or implied, with respect to the Website, and all information and functionalities contained therein.
IN NO EVENT SHALL CAPE CAPITAL BE LIABLE FOR ANY DIRECT, INDIRECT, INCIDENTAL, SPECIAL, PUNITIVE, CONSEQUENTIAL OR OTHER DAMAGES (INCLUDING WITHOUT LIMITATION DAMAGES FOR LOSS OF DATA, BUSINESS OR PROFITS) ARISING OUT OF OR IN CONNECTION WITH THESE CONDITIONS, THIS WEBSITE, THE INABILITY TO USE THIS WEBSITE OR ANY INFORMATION OBTAINED OR STORED THERFROM. Cape Capital excludes any liability for any loss, damage or alteration of any kind including but not limited to transmission to losses, delays, misunderstandings, unauthorized interception by third parties, duplication or fraud, except in the event of gross negligence on the part of Cape Capital. Any transmission or download of information is entirely at your own risk.
The hyperlinks on the Website are only provided for information and convenience purposes. Cape Capital is not responsible for the content of external websites that link or are accessible from this Website. Cape Capital does not assume any responsibility or liability with respect to any website accessed via this Website. Please note that when you click on any external website’s hypertext link you will leave this Website. You should review the privacy statements of such websites carefully before you provide any personal or confidential information.
The use of electronic communication channels, in particular unencrypted e-mails and text messages, is associated with various risks which may include, but are not limited to, the risk of transmission errors, alterations or duplications, the risk of interception or manipulation of content and the risk of introducing malicious software (malware) by unauthorized third parties. By using such electronic communication channels, you accept these risks and agree to bear any resulting losses or damages.
Cape Capital has established a Cape Capital Privacy Notice, which forms an integral part of these Conditions. It explains how personal data is collected and processed at Cape Capital, including this Website. Cape Capital uses cookies to personalize and improve site experience. You can at any time change or withdraw your consent from the Cookie Declaration on the Website. Your consent applies to the following domains: capecapital.com. Your current state: Consent accepted or Consent rejected. Manage your consent.
The access and use of this Website, and these present Conditions are governed by substantive Swiss law with the exclusion of the conflict of law principles. The place of jurisdiction is Zurich, Switzerland.
Last Update: October 2024
Psychedelics reset the brain through dream-like experiences—Sean McLintock believes they are the next big medical breakthrough for mental health
Perhaps best-known as the hallucinogenic, trippy narcotic of choice at underground raves in the 1960s, in recent years, psychedelics—which were classified as Schedule 1 drugs a decade later, effectively restricting all medical research—have re-emerged as a potential life-changing treatment for those with mental health and chronic pain issues.
‘The reason we are looking for alternatives is the scale of unmet need,’ says Sean McLintock, a founding partner of Neo Kuma Ventures, which invests in early-stage psychedelic healthcare companies.
According to the World Health Organisation, around 280 million people globally suffer from depression, and of these, King’s College London states that approximately a third have treatment-resistant depression (meaning they haven’t responded to at least two types of antidepressants). Even prior to Covid-19, a World Economic Forum report calculated that poor mental health is estimated to cost the economy over a trillion dollars per year in lost productivity.
‘SSRIs, a class of drug commonly used to treat depression and anxiety, build up the level of serotonin in the brain over time but they only cover up the symptoms of someone’s underlying trauma and have limited efficacy. Psychedelics are different in that they can reset the root cause,’ continues Sean.
'She kicked alcohol and stayed sober until the end of her life. It woke me up to the potential of these medicines’
He first became interested in the subject after his late mother struggled with alcoholism. ‘We tried everything as a family and nothing worked. Then, when I was 22 and finishing my law degree in South Africa, I read about a microdosing study in Switzerland on psilocybin, the active ingredient in magic mushrooms. She took part and afterwards was a completely different person. She kicked alcohol and stayed sober until the end of her life. It woke me up to the potential of these medicines.’
Psychedelics alter perception and mood by promoting new pathways between neurons. ‘The best way I’ve heard it described is like shaking a snow globe and when the flakes settle, they are in different patterns,’ says Sean. The experience of taking them is often likened to being in a spiritual, mystical, dreamlike state. ‘Brain-imaging studies are helping us to understand what is happening, not only in psychedelics but also in dream states.’
Three key psychedelics have been given rare breakthrough status by the Food and Drug Administration (FDA): ketamine, MDMA and psilocybin. Of these, the only one that is available so far is Spravato, a ketamine-based nasal spray brought to market by Johnson & Johnson and authorised for use in Europe, the US and Canada to reduce symptoms in patients with major depressive disorder. It’s also accessible off-label, which means that although it’s not approved for other indications, it is allowed to be used because it’s deemed safe.
Then there’s MDMA, which is being trialled by the Multidisciplinary Association for Psychedelic Studies (MAPS). It has passed its second Phase 3 trial which resulted in 67 percent of participants given the drug no longer meeting the diagnostic criteria for PTSD after three sessions, compared with 32 percent of those in the placebo group. ‘That should be in the market within 18 months and will be a massive catalyst for the industry,’ says Sean. ‘It’s going to get really serious for psychedelics after that.’
Finally, the end of last year saw the results of the largest trial of psilocybin to date, led by COMPASS Pathways and published in The New England Journal of Medicine. It showed that after a single dose of psilocybin therapy, around 30 percent of patients with treatment-resistant depression were in remission at week three. If the trials continue to progress well, that should be on the market in around four years.
‘There are around 50 drugs currently undergoing clinical trials and most of these are happening in the US, which is the biggest market for any drug,’ says Sean. ‘After the US, we expect the EU and the UK to be the second and third largest markets for psychedelics. We’re also seeing interesting stuff happen in countries like Australia where, from July this year, therapists can request approval to treat patients with either psilocybin or MDMA for mental health conditions.’
'It’s easy to box psychedelics off as wacky'
The research renaissance was kickstarted at the beginning of this century by doctors affiliated with Johns Hopkins University in the US. It continued at Imperial College London and then proliferated around the world as credibility grew.
‘It’s easy to box psychedelics off as wacky but many of those working in this area have strong backgrounds in neuroscience. What we’re seeing is an application of some of the world’s best and brightest minds to understand these drugs,’ says Sean, who is working with a number of government lobbying institutions that are trying to change the scheduling of psychedelics at UN level. ‘This has combined with people travelling to places such as Peru, Brazil and Costa Rica to have these treatments in a legal setting. Anecdotal reports coming back to the mainstream and social media spurred a social momentum which has latched onto the scientific interest and now we’ve seen a lot of regulatory and legislative momentum follow suit.
However, he draws a clear distinction between those who are treated medically by an approved drug versus legalised retreats or recreational use. ‘Legalised retreats are not what we invest in. While some are brilliant businesses offering strong guidance and support to their clients, that is not the side of the industry we support. We’re for the use of these drugs in a very controlled clinical setting. I think when you put it in that context and look at the efficacy results of the scientific studies, it’s very difficult for a politician or regulatory arm to not want to take them forward.’
Nevertheless, one of the major roadblocks to psychedelics is still their perception amongst psychiatrists, general practitioners, and psychologists. ‘They are going to be the ones advocating these treatments on the ground so I think greater education and communication of the efficacy of the trials is needed. The hurdle of winning over clinicians who are used to prescribing SSRIs as a frontline treatment is going to take time,’ he says.
Sean cites other hurdles, including the expense of clinical trials; the need for companies to partner with pharmaceuticals who will have to be convinced of the commercial value of psychedelics; and, perhaps biggest of all, the need to train clinicians in this new type of combination therapy. ‘With psilocybin for instance, patients usually have a six-hour session with two therapists and that’s burdensome on the healthcare system. The roadblock will be justifying that upfront cost as a pay-off compared to the drugs someone would take throughout their lifetime,’ he says.
The potential reward though, is great. He concludes: ‘We’re working towards a world where if you’re suffering from a condition like PTSD or depression, there are a number of treatment options. None of them are a silver bullet but in the next decade more will enter the medical arena and be widely adopted—and that’s a positive thing.’
Sean McLintock
Founding Partner of Neo Kuma Ventures